News Focus
News Focus
Replies to #3761 on FDA Plays
icon url

2H2

05/06/10 2:07 PM

#3764 RE: cccpmd666 #3761

POZN, I was away last week at a convention in (now flooded) Nashville so I was not able to watch the markets. Set a sell stop at $11.50 and of course got taken out with the bear raid. I was furious to say the least to see what happened, but looking back, it was a blessing.

Once POZN stabilizes, I will be back in for sure.

HH
icon url

FDA_Player

05/06/10 2:17 PM

#3766 RE: cccpmd666 #3761

what do you mean with LOD?
icon url

FDA_Player

05/06/10 2:23 PM

#3769 RE: cccpmd666 #3761

you think its a good taktik to buy when it is over with falling?

will it go at 5-7$ ?

how about this:

We continue to be very positive on the Pozen story. The royalty payments off Vimovo and Treximet should drive the company to cash flow positive operations in 2011. The Vimovo approval also validates the pathway for Pozen’s phase III PA-325/40 product, another potential $500+ million idea. Millions of people are taking daily aspirin for cardiovascular secondary prevention, the majority without a gastro-protectant.

PA offers significantly improved GI tolerability to enteric-coated aspirin, and the potential to increase the dose to therapeutic levels that can also treat pain and may reduce the risk of pre-cancerous colon adenomas. We see Pozen fairly-valued at $15 per share